Flexible Stenting Solutions Inc. Announces IDE Submission for FlexStent(R) Femoropopliteal Self Expanding Stent System

EATONTOWN, N.J.--(BUSINESS WIRE)--Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial stents has submitted an Investigational Device Exemption (IDE) application to the FDA for its FlexStent® Femoropopliteal SE Stent System for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries. This next generation femoropopliteal stent and delivery system can significantly improve patient care in the high growth peripheral vascular segment.